[go: up one dir, main page]

MX2021002261A - Formas cristalinas de 3-(imidazo[1,2-b] piridazin-3- iletinil)-4-metil-n-(4-[(4-metilpiperazin-1-il) metil]-3-(trifluorometil)fenil) benzamida y su sal de monoclorhidrato. - Google Patents

Formas cristalinas de 3-(imidazo[1,2-b] piridazin-3- iletinil)-4-metil-n-(4-[(4-metilpiperazin-1-il) metil]-3-(trifluorometil)fenil) benzamida y su sal de monoclorhidrato.

Info

Publication number
MX2021002261A
MX2021002261A MX2021002261A MX2021002261A MX2021002261A MX 2021002261 A MX2021002261 A MX 2021002261A MX 2021002261 A MX2021002261 A MX 2021002261A MX 2021002261 A MX2021002261 A MX 2021002261A MX 2021002261 A MX2021002261 A MX 2021002261A
Authority
MX
Mexico
Prior art keywords
methyl
ylethynyl
pyridazin
imidazo
trifluoromethyl
Prior art date
Application number
MX2021002261A
Other languages
English (en)
Inventor
Christopher K Murray
Leonard W Rozamus
John J Chaber
Pradeep Sharma
Original Assignee
Ariad Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50929140&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2021002261(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ariad Pharma Inc filed Critical Ariad Pharma Inc
Publication of MX2021002261A publication Critical patent/MX2021002261A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente describe formas cristalinas novedosas de la base libre de 3-(imidazo[1,2-b]piridazin-3-iletinil)-4-metil-N-{4-[(4-m etilpiperazin-1-il)metil]-3-(trifluorometil)fenil}benzamida y monoclorhidrato de 3-(imidazo[1,2-b]piridazin-3-iletinil)-4-metil- N-{4-[(4-metilpiperazin-1-il)metil]-3-(trifluorometil)fenil}benza mida, sus composiciones farmacéuticas y métodos para su preparación y uso.
MX2021002261A 2012-12-12 2015-06-12 Formas cristalinas de 3-(imidazo[1,2-b] piridazin-3- iletinil)-4-metil-n-(4-[(4-metilpiperazin-1-il) metil]-3-(trifluorometil)fenil) benzamida y su sal de monoclorhidrato. MX2021002261A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261736543P 2012-12-12 2012-12-12
US201261737007P 2012-12-13 2012-12-13
US201361788208P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
MX2021002261A true MX2021002261A (es) 2021-05-27

Family

ID=50929140

Family Applications (10)

Application Number Title Priority Date Filing Date
MX2015007578A MX359147B (es) 2012-12-12 2013-12-12 Formas cristalinas de 3-(imidazo[1,2-b] piridazin-3-iletinil)-4-me til-n-(4-[ (4-metilpiperazin-1-il) metil]-3-(trifluorometil) fenil) benzamida y su sal de monoclorhidrato.
MX2021002253A MX2021002253A (es) 2012-12-12 2015-06-12 Formas cristalinas de 3-(imidazo[1,2-b] piridazin-3- iletinil)-4-metil-n-(4-[(4-metilpiperazin-1-il) metil]-3-(trifluorometil)fenil) benzamida y su sal de monoclorhidrato.
MX2021002254A MX2021002254A (es) 2012-12-12 2015-06-12 Formas cristalinas de 3-(imidazo[1,2-b] piridazin-3- iletinil)-4-metil-n-(4-[(4-metilpiperazin-1-il) metil]-3-(trifluorometil)fenil) benzamida y su sal de monoclorhidrato.
MX2021002256A MX2021002256A (es) 2012-12-12 2015-06-12 Formas cristalinas de 3-(imidazo[1,2-b] piridazin-3- iletinil)-4-metil-n-(4-[(4-metilpiperazin-1-il) metil]-3-(trifluorometil)fenil) benzamida y su sal de monoclorhidrato.
MX2021002255A MX2021002255A (es) 2012-12-12 2015-06-12 Formas cristalinas de 3-(imidazo[1,2-b] piridazin-3- iletinil)-4-metil-n-(4-[(4-metilpiperazin-1-il) metil]-3-(trifluorometil)fenil) benzamida y su sal de monoclorhidrato.
MX2021002257A MX2021002257A (es) 2012-12-12 2015-06-12 Formas cristalinas de 3-(imidazo[1,2-b] piridazin-3- iletinil)-4-metil-n-(4-[(4-metilpiperazin-1-il) metil]-3-(trifluorometil)fenil) benzamida y su sal de monoclorhidrato.
MX2021002264A MX2021002264A (es) 2012-12-12 2015-06-12 Formas cristalinas de 3-(imidazo[1,2-b] piridazin-3- iletinil)-4-metil-n-(4-[(4-metilpiperazin-1-il) metil]-3-(trifluorometil)fenil) benzamida y su sal de monoclorhidrato.
MX2021002259A MX2021002259A (es) 2012-12-12 2015-06-12 Formas cristalinas de 3-(imidazo[1,2-b] piridazin-3- iletinil)-4-metil-n-(4-[(4-metilpiperazin-1-il) metil]-3-(trifluorometil)fenil) benzamida y su sal de monoclorhidrato.
MX2021002261A MX2021002261A (es) 2012-12-12 2015-06-12 Formas cristalinas de 3-(imidazo[1,2-b] piridazin-3- iletinil)-4-metil-n-(4-[(4-metilpiperazin-1-il) metil]-3-(trifluorometil)fenil) benzamida y su sal de monoclorhidrato.
MX2021002258A MX2021002258A (es) 2012-12-12 2015-06-12 Formas cristalinas de 3-(imidazo[1,2-b] piridazin-3- iletinil)-4-metil-n-(4-[(4-metilpiperazin-1-il) metil]-3-(trifluorometil)fenil) benzamida y su sal de monoclorhidrato.

Family Applications Before (8)

Application Number Title Priority Date Filing Date
MX2015007578A MX359147B (es) 2012-12-12 2013-12-12 Formas cristalinas de 3-(imidazo[1,2-b] piridazin-3-iletinil)-4-me til-n-(4-[ (4-metilpiperazin-1-il) metil]-3-(trifluorometil) fenil) benzamida y su sal de monoclorhidrato.
MX2021002253A MX2021002253A (es) 2012-12-12 2015-06-12 Formas cristalinas de 3-(imidazo[1,2-b] piridazin-3- iletinil)-4-metil-n-(4-[(4-metilpiperazin-1-il) metil]-3-(trifluorometil)fenil) benzamida y su sal de monoclorhidrato.
MX2021002254A MX2021002254A (es) 2012-12-12 2015-06-12 Formas cristalinas de 3-(imidazo[1,2-b] piridazin-3- iletinil)-4-metil-n-(4-[(4-metilpiperazin-1-il) metil]-3-(trifluorometil)fenil) benzamida y su sal de monoclorhidrato.
MX2021002256A MX2021002256A (es) 2012-12-12 2015-06-12 Formas cristalinas de 3-(imidazo[1,2-b] piridazin-3- iletinil)-4-metil-n-(4-[(4-metilpiperazin-1-il) metil]-3-(trifluorometil)fenil) benzamida y su sal de monoclorhidrato.
MX2021002255A MX2021002255A (es) 2012-12-12 2015-06-12 Formas cristalinas de 3-(imidazo[1,2-b] piridazin-3- iletinil)-4-metil-n-(4-[(4-metilpiperazin-1-il) metil]-3-(trifluorometil)fenil) benzamida y su sal de monoclorhidrato.
MX2021002257A MX2021002257A (es) 2012-12-12 2015-06-12 Formas cristalinas de 3-(imidazo[1,2-b] piridazin-3- iletinil)-4-metil-n-(4-[(4-metilpiperazin-1-il) metil]-3-(trifluorometil)fenil) benzamida y su sal de monoclorhidrato.
MX2021002264A MX2021002264A (es) 2012-12-12 2015-06-12 Formas cristalinas de 3-(imidazo[1,2-b] piridazin-3- iletinil)-4-metil-n-(4-[(4-metilpiperazin-1-il) metil]-3-(trifluorometil)fenil) benzamida y su sal de monoclorhidrato.
MX2021002259A MX2021002259A (es) 2012-12-12 2015-06-12 Formas cristalinas de 3-(imidazo[1,2-b] piridazin-3- iletinil)-4-metil-n-(4-[(4-metilpiperazin-1-il) metil]-3-(trifluorometil)fenil) benzamida y su sal de monoclorhidrato.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021002258A MX2021002258A (es) 2012-12-12 2015-06-12 Formas cristalinas de 3-(imidazo[1,2-b] piridazin-3- iletinil)-4-metil-n-(4-[(4-metilpiperazin-1-il) metil]-3-(trifluorometil)fenil) benzamida y su sal de monoclorhidrato.

Country Status (9)

Country Link
US (9) US9493470B2 (es)
JP (4) JP6447508B2 (es)
CN (2) CN115043843A (es)
CA (3) CA3022250A1 (es)
CL (1) CL2015001643A1 (es)
HK (1) HK1218878A1 (es)
MX (10) MX359147B (es)
NZ (1) NZ709648A (es)
WO (2) WO2014093583A2 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX343042B (es) 2005-12-23 2016-10-21 Ariad Pharma Inc Compuestos heteroarilicos biciclicos.
TWI568722B (zh) 2012-06-15 2017-02-01 葛蘭馬克製藥公司 作爲ｍＰＧＥＳ－１抑制劑之三唑酮化合物
CA3022250A1 (en) * 2012-12-12 2014-06-12 Ariad Pharmaceuticals, Inc. Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride
AU2014286047B2 (en) * 2013-07-04 2018-02-08 Sandoz Ag Crystalline forms of ponatinib hydrochloride
CN104496995A (zh) * 2014-01-06 2015-04-08 广东东阳光药业有限公司 制备3-乙炔基咪唑并[1,2-b]哒嗪的方法
CA3047107A1 (en) * 2016-12-15 2018-06-21 Ariad Pharmaceuticals, Inc. Benzimidazole compounds as c-kit inhibitors
US10221184B2 (en) 2017-01-20 2019-03-05 Apicore Us Llc Polymorphs of ponatinib hydrochloride
CA3067271A1 (en) * 2017-06-20 2018-12-27 Apotex Inc. Crystalline forms of ponatinib hydrochloride
AU2019249121B2 (en) * 2018-04-02 2024-05-02 Stealth Biotherapeutics Inc. Crystalline dipeptides useful in the synthesis of elamipretide
EP3781568A1 (en) 2018-06-22 2021-02-24 Johnson Matthey Public Limited Company Form of ponatinib
MX2021005011A (es) 2018-11-01 2021-07-21 Syros Pharmaceuticals Inc Métodos de tratamiento del cáncer en pacientes identificados por biomarcadores con inhibidores no covalentes de cinasa 7 dependiente de ciclina (cdk7).
WO2020223235A1 (en) 2019-04-29 2020-11-05 Incyte Corporation Mini-tablet dosage forms of ponatinib
CN111004240B (zh) * 2019-12-13 2020-12-01 山东铂源药业有限公司 一种泊那替尼中间体3-乙炔基咪唑并[1,2-b]哒嗪的合成方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5099067A (en) 1988-08-05 1992-03-24 Northwestern University Use of ammonium formate as a hydrogen transfer reagent for reduction of chiral nitro compounds with retention of configuration
MXPA02004545A (es) 1999-11-08 2002-09-02 Schering Corp Procedimiento para preparar n-( a-hidroxifenil)-n'-(4'-aminofenil)-piperazina.
HN2001000008A (es) 2000-01-21 2003-12-11 Inc Agouron Pharmaceuticals Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo
DE10021246A1 (de) 2000-04-25 2001-10-31 Schering Ag Substituierte Benzoesäureamide und deren Verwendung als Arzneimittel
IL159811A0 (en) 2001-07-13 2004-06-20 Neurogen Corp Heteroaryl substituted fused bicyclic heteroaryl compounds as gabaa receptor ligands
TW200418466A (en) 2002-11-06 2004-10-01 Smithkline Beecham Corp Chemical compounds
GB0230089D0 (en) 2002-12-24 2003-01-29 Astrazeneca Ab Therapeutic agents
CA2546673A1 (en) 2003-11-28 2005-06-09 Novartis Ag Diaryl urea derivatives in the treatment of protein kinase dependent diseases
WO2005056571A1 (en) 2003-12-05 2005-06-23 Biovitrum Ab Improved synthesis of 2-substituted adenosines
ATE415970T1 (de) 2003-12-24 2008-12-15 Astrazeneca Ab Pyrimidine mit tie2 (tek) aktivität
US20080027076A1 (en) 2003-12-24 2008-01-31 Astrazeneca Ab Pyrimidines With Tie2 (Tek) Activity
US7947851B2 (en) 2004-04-07 2011-05-24 Merck Serono Sa 1,1′-(1,2-ethynediyl)bis-benzene derivatives as PTP 1-B inhibitors
MX2007000481A (es) 2004-07-14 2007-03-29 Ptc Therapeutics Inc Metodos para tratar hepatitis c.
US7776869B2 (en) 2004-10-18 2010-08-17 Amgen Inc. Heteroaryl-substituted alkyne compounds and method of use
GB0502418D0 (en) 2005-02-05 2005-03-16 Astrazeneca Ab Compounds
JP2008534565A (ja) 2005-03-31 2008-08-28 アストラゼネカ アクチボラグ Ｔｉｅ２阻害活性のあるアミノピリミジン誘導体
JP2009502734A (ja) 2005-07-29 2009-01-29 アステラス製薬株式会社 Ｌｃｋ阻害剤としての縮合複素環
WO2007021937A2 (en) 2005-08-11 2007-02-22 Ariad Pharmaceuticals, Inc. Unsaturated heterocyclic derivatives
SI1973545T1 (sl) * 2005-12-23 2013-04-30 Ariad Pharmaceuticals, Inc. Spojine bicikličnega heteroarila
MX343042B (es) 2005-12-23 2016-10-21 Ariad Pharma Inc Compuestos heteroarilicos biciclicos.
EP2023933A4 (en) 2006-05-08 2011-02-23 Ariad Pharma Inc HETEROARYL ACETYLENE COMPOUNDS
ES2555515T3 (es) 2006-05-08 2016-01-04 Ariad Pharmaceuticals, Inc. Compuestos de heteroarilo monocíclico
EP2107054A1 (en) 2008-04-01 2009-10-07 Università Degli Studi Di Milano - Bicocca Antiproliferative compounds and therapeutic uses thereof
WO2010124047A1 (en) 2009-04-23 2010-10-28 Wyeth Llc Bisaryl alkynylamides as negative allosteric modulators of metabotropic glutamate receptor 5 (mglur5)
US8329724B2 (en) 2009-08-03 2012-12-11 Hoffmann-La Roche Inc. Process for the manufacture of pharmaceutically active compounds
EP2762142A1 (en) * 2009-10-30 2014-08-06 ARIAD Pharmaceuticals, Inc. Compositions for treating cancer
BR112013024171A2 (pt) 2011-04-07 2016-12-13 Ariad Pharma Inc método para o tratamento e prevenção de uma condição neurodegenerativa
WO2013101281A1 (en) 2011-04-07 2013-07-04 Ariad Pharmaceuticals, Inc. Methods and compositions for treating parkinson's disease
JP2015514802A (ja) 2012-04-25 2015-05-21 アリアド・ファーマシューティカルズ・インコーポレイテッド Ｒａｆキナーゼ媒介疾患用の方法及び組成物
CA3022250A1 (en) * 2012-12-12 2014-06-12 Ariad Pharmaceuticals, Inc. Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride

Also Published As

Publication number Publication date
MX2021002253A (es) 2021-05-27
WO2014093583A2 (en) 2014-06-19
US20240083902A1 (en) 2024-03-14
US20170190707A1 (en) 2017-07-06
MX359147B (es) 2018-09-17
HK1218878A1 (zh) 2017-03-17
JP7352841B2 (ja) 2023-09-29
US20210340149A1 (en) 2021-11-04
MX2021002258A (es) 2021-05-27
US11384086B2 (en) 2022-07-12
US9493470B2 (en) 2016-11-15
CA3022250A1 (en) 2014-06-12
US20210277012A1 (en) 2021-09-09
JP2016503010A (ja) 2016-02-01
US11279705B2 (en) 2022-03-22
JP2022037122A (ja) 2022-03-08
CN105188701A (zh) 2015-12-23
MX2021002259A (es) 2021-05-27
US11192897B2 (en) 2021-12-07
MX2021002255A (es) 2021-05-27
JP2023179498A (ja) 2023-12-19
WO2014093579A2 (en) 2014-06-19
CN115043843A (zh) 2022-09-13
US10125136B2 (en) 2018-11-13
JP2018168191A (ja) 2018-11-01
US10662197B2 (en) 2020-05-26
CL2015001643A1 (es) 2015-10-02
US20190169196A1 (en) 2019-06-06
CA2815506A1 (en) 2014-06-12
MX2021002254A (es) 2021-05-27
MX2021002256A (es) 2021-05-27
WO2014093579A3 (en) 2014-07-10
MX2021002257A (es) 2021-05-27
US11192895B2 (en) 2021-12-07
US20210024527A1 (en) 2021-01-28
NZ709648A (en) 2020-05-29
MX2015007578A (es) 2016-03-21
JP7042175B2 (ja) 2022-03-25
CA3167093A1 (en) 2014-06-12
US20210277011A1 (en) 2021-09-09
CA2815506C (en) 2018-12-11
MX2021002264A (es) 2021-05-27
US20150315194A1 (en) 2015-11-05
US20210277010A1 (en) 2021-09-09
WO2014093583A3 (en) 2014-08-07
JP6447508B2 (ja) 2019-01-09
US11192896B2 (en) 2021-12-07

Similar Documents

Publication Publication Date Title
MX2021002253A (es) Formas cristalinas de 3-(imidazo[1,2-b] piridazin-3- iletinil)-4-metil-n-(4-[(4-metilpiperazin-1-il) metil]-3-(trifluorometil)fenil) benzamida y su sal de monoclorhidrato.
PH12017500166A1 (en) 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as btk-inhibitors
NZ631112A (en) Crystalline bromodomain inhibitors
UA112317C2 (uk) Похідні 2-(1,2,3-триазол-2-іл)бензаміду та 3-(1,2,3-триазол-2-іл)піколінаміду як антагоністи рецептора орексину
IN2014DN09352A (es)
EA201691242A1 (ru) Фармацевтические композиции, содержащие azd9291
IN2014DN09348A (es)
SG194756A1 (en) Modified release of 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-5-(4-methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide solubilized using organic acids
HK1214822A1 (zh) 新型 苄氧基 苯基 己- -炔酸衍生物、其製備方法、和包括其作為有效成分的用於預防和治療代謝性疾病的藥物組合物
IN2014DN09347A (es)
PH12018501331A1 (en) Crystalline forms of thienopyrimidine compound
PH12017501832A1 (en) Stabilized pharmaceutical composition
EA201500446A1 (ru) Фармацевтическая композиция для снижения уровня n-оксида триметиламина
MX2014002141A (es) Carboxamidas de n-(5-cicloalquil - o 5-heterociclil-)-piridin-3-il o.
IN2013CH01248A (es)
TN2013000440A1 (en) Modified release of 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-5-(4-methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide solubilized using organic acids